HK Stock Market Move | PCCW (00008) fell nearly 3%, with mid-term shareholder losses narrowing by 38% year-on-year. The company will accelerate the application of AI in its network and operational processes.
PCCW (00008) fell nearly 3%. As of the time of writing, it dropped 2.55%, priced at HK$5.725, with a transaction value of HK$39.0171 million.
PCCW (00008) fell nearly 3%, and at the time of writing, it was down 2.55%, priced at HKD 5.725, with a transaction volume of HKD 39.0171 million.
In terms of news, PCCW recently announced its financial performance for the six months ending June 30, 2026. The group achieved a total comprehensive income of HKD 20.204 billion during the period, an increase of 7% year-on-year; the loss attributable to equity holders of the company narrowed to HKD 276 million, down 38% year-on-year; basic loss per share was HKD 0.0357. The announcement stated that PCCW would accelerate the application of AI in its network and operational processes, integrating AI into personal and enterprise customer services to enhance operational efficiency and service quality, as well as explore new growth opportunities.
For the six months ending June 30, 2026, revenue from international telecommunications services grew by 2% to HKD 38.99 billion, mainly driven by increased revenue from data and international voice wholesale, as well as rising demand for the companys Console Connect software-defined cloud interconnection platform services. Notably, the demand for the companys services from OTT users in mainland China experienced healthy growth, with revenue increasing by over 50%.
Related Articles
HK Stock Market Move | PHANCY (06682) rose over 4% in the late trading session as the company leads a smart body innovation project in Beijing to build an enterprise-level ecological platform.

Wuhan Hiteck Biological Pharma (300683.SZ) has approved its subsidiary ZM-02 eye injection to conduct clinical trials.

Shandong Weigao Blood Purification Products (603014.SH): The issuance of shares to purchase assets will be discussed in the meeting on August 10.
HK Stock Market Move | PHANCY (06682) rose over 4% in the late trading session as the company leads a smart body innovation project in Beijing to build an enterprise-level ecological platform.
Wuhan Hiteck Biological Pharma (300683.SZ) has approved its subsidiary ZM-02 eye injection to conduct clinical trials.

Shandong Weigao Blood Purification Products (603014.SH): The issuance of shares to purchase assets will be discussed in the meeting on August 10.

RECOMMEND





